CN107281212A - A kind of jujube complex polysaccharide composition and its preparation method and application - Google Patents
A kind of jujube complex polysaccharide composition and its preparation method and application Download PDFInfo
- Publication number
- CN107281212A CN107281212A CN201710465590.9A CN201710465590A CN107281212A CN 107281212 A CN107281212 A CN 107281212A CN 201710465590 A CN201710465590 A CN 201710465590A CN 107281212 A CN107281212 A CN 107281212A
- Authority
- CN
- China
- Prior art keywords
- extract
- polysaccharide
- jujube
- parts
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 183
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 183
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 183
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 240000008866 Ziziphus nummularia Species 0.000 title abstract 3
- 241001506047 Tremella Species 0.000 claims abstract description 50
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 44
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 44
- 230000007935 neutral effect Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 21
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 16
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 168
- 241001247821 Ziziphus Species 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 238000000605 extraction Methods 0.000 claims description 38
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 238000007654 immersion Methods 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 230000036039 immunity Effects 0.000 abstract description 10
- 206010012735 Diarrhoea Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 5
- 239000002699 waste material Substances 0.000 abstract description 5
- 244000241872 Lycium chinense Species 0.000 abstract description 4
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 206010047700 Vomiting Diseases 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 235000015096 spirit Nutrition 0.000 abstract description 4
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 abstract description 3
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- 244000241838 Lycium barbarum Species 0.000 description 29
- 235000015459 Lycium barbarum Nutrition 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 17
- 238000010992 reflux Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 239000005913 Maltodextrin Substances 0.000 description 7
- 229920002774 Maltodextrin Polymers 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 229940035034 maltodextrin Drugs 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002379 periodontal ligament Anatomy 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 241000608867 Leucogenes Species 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000388 leucogen effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UJTIFEVFUCJMKZ-UHFFFAOYSA-N benzoic acid;sodium Chemical compound [Na].OC(=O)C1=CC=CC=C1 UJTIFEVFUCJMKZ-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 galactolipin Chemical compound 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000000292 leukogenic effect Effects 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of jujube complex polysaccharide composition of the present invention and its preparation method and application, the present invention uses jujube, Tremella fructification, the fruit of Chinese wolfberry, pseudo-ginseng respectively, pseudo-ginseng is the waste residue for extracting arasaponin, date polysaccharide, tremella polysaccharides, LBP-X, neutral notoginseng polysaccharide are extracted, yield is respectively 6.5 6.9%, 12.0 21.0%, 2.8 4.4%, 0.32 0.42%.It is respectively 48 58%, 37 41%, 28 34%, 80 94% that sulfuric acid anthrone method, which determines polyoses content,.This formula contributes to immunocompromised person and tumor patient strengthen immunity, improves the symptoms such as One's spirits are drooping, physically weak weak, appetite reduction, nausea and vomiting, loose stool diarrhea, irritated insomnia, effectively mitigates the harm of chemicotherapy and operation to tumour patient.
Description
Technical field
The invention belongs to field of medicaments, it is related to a kind of jujube complex polysaccharide composition and its preparation method and application.
Background technology
According to the website (http of the World Health Organization://www.who.int/mediacentre/factsheets/fs297/
Zh/) No. 297 display of cancer commentary in 2 months in 2015：Cancer is whole world morbidity and main causes of death.In 184 states
In family and area, Chinese Cancer Mortality occupies medium level on the upper side in general, and number of the infected accounts for the whole world
21.8%.With aging population aggravation and socio-economic development, industrialization, urbanization process are accelerated, environmental factor, life side
Formula constantly changes, and the situation is tense for China's tumour prevention and control.
In recent years, with the development of biotechnology, tumour immunotherapy turns into after tumor operation, and radiotherapy, chemotherapy, targeting is controlled
Being most hopeful after treatment can successfully cure the means of cancer, be even more within this several years to achieve major progress, at present, to target PD-1/
PD-L1 Antybody therapy, it is a variety of pernicious in melanoma, non-small cell lung cancer, stomach cancer, liver cancer, carcinoma of urinary bladder and lymthoma etc.
Tumour all shows good curative effect.Malignant tumour immunization therapy is given and reported by Science, Nature as breakthrough
Road.
Easily cause Neuroleptic Leukocytopenia, clinical rush leucocyte medicine conventional at present, such as leucogen, shark during chemotherapy of tumors
Liver alcohol etc., effect is slow, and effect is not notable.Though and inject the leukogenic effects such as class medicine G-CSF significantly, there is rebound phenomenon,
The side reactions such as ostalgia, heating occur during heavy dose application, and price is relatively expensive.Therefore eager demand determined curative effect, valency of fine quality
Honest and clean, Small side effects medicines.
The traditional Chinese medical science goes to treat the traditional idea of disease (including tumour) from the angle for recovering body equilibrium between yin and yang, with modern medicine
Tumour immunotherapy realizes that it is wonderful that the thinking of homeostasis plays the same tune on different musical instruments from regulation immune function of human body.The traditional Chinese medical science thinks
" heresy is gathered, and its gas must be empty ", why disease and evil can be invaded under the imbalance of yin and yang that human body is mostly due to people itself, immunity
Drop.Negative and positive are corrected by medicine, strengthening the body resistance to consolidate the constitution is only cure the disease basic.Ginseng, the Radix Astragali, ganoderma lucidum etc. are much rich in the benefit of polysaccharide
Beneficial class Chinese medicine is widely used in the various diseases including tumour.
Polysaccharide is widely present in animal, plant and microorganism.One of constituent as living matter, it joins extensively
The transmission and impression of information between various biological phenomenas and the regulation of physiology course with cell, such as immunocyte, turn of cell
The activities such as change, division and regeneration.Polysaccharide has antiviral, anti-infective, antitumor, anti-oxidant, radioresistance, hypoglycemic, liver protection, tune
Section is immune to wait physiologically active.A large amount of pharmacology and clinical research show that polysaccharide is a kind of immunomodulator, it can activate it is immune by
Body, improves the immunologic function of body, realizes antineoplastic function.
Number of patent application discloses for 201210532229.0 patent of invention and provides a kind of strengthen immunity of contributing to
Health preserving health-care food formula and preparation method thereof.It includes the raw material of following ratio of weight and number：1000 parts of the fruit of Chinese wolfberry, sealwort 1000
Part, 1000 parts of Poria cocos, 1500 parts of Chinese yam, 1000 parts of mulberries, 1000 parts of jujube, 600 parts of donkey-hide gelatin, 600 parts of white fungus.It is prepared by the invention
Technique uses traditional water decoction extraction method, and function is single, the DeGrain in terms of immunity is improved.
The content of the invention
In order to overcome the deficiencies in the prior art, the present invention provides a kind of jujube complex polysaccharide composition of the invention and its preparation
Methods and applications, the present invention uses jujube, Tremella fructification, the fruit of Chinese wolfberry, pseudo-ginseng respectively, and pseudo-ginseng is to extract giving up for arasaponin
Slag, extracts date polysaccharide, tremella polysaccharides, LBP-X, neutral notoginseng polysaccharide, yield is respectively 6.5-6.9%, 12.0-
21.0%th, 2.8-4.4%, 0.32-0.42%, it is respectively 48-58%, 37-41%, 28- that H2SO4-anthrone method, which determines polyoses content,
34%th, 80-94%.This formula contributes to immunocompromised person and tumor patient strengthen immunity, improves One's spirits are drooping, physically weak weary
The symptoms such as power, appetite reduction, nausea and vomiting, loose stool diarrhea, irritated insomnia, effectively mitigate chemicotherapy and perform the operation to tumour patient
Harm.
The invention provides following technical scheme：
A kind of jujube complex polysaccharide composition, is made by mixing using plurality of raw materials extract and formed, including date polysaccharide is carried
Take thing, Lycium barbarum polysaccharide extract and tremella polysaccharides extract, neutral notoginseng polysaccharide extract.
Preferably, the extract of following parts by weight is included:0.5-5 parts of date polysaccharide extract, Lycium barbarum polysaccharide extract
0.5-5 parts, 0.5-5 parts of tremella polysaccharides extract, neutral 0-5 parts of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:4.5 parts of date polysaccharide extract, matrimony vine
1 part of polyoses extract, 4.5 parts of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:4.5 parts of date polysaccharide extract, matrimony vine
1 part of polyoses extract, 4.5 parts of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:2 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 2 parts of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:2 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 2 parts of tremella polysaccharides extract, neutral 2 parts of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:2 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:2 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:3 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:3 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:4 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:4 parts of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
2 parts of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
2 parts of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
3 parts of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
3 parts of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
4 parts of sugar extract, 1 part of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
4 parts of sugar extract, 1 part of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 2 parts of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 2 parts of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 3 parts of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 3 parts of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 4 parts of tremella polysaccharides extract.
Any of the above-described scheme is preferably, and includes the extract of following parts by weight:1 part of date polysaccharide extract, matrimony vine are more
1 part of sugar extract, 4 parts of tremella polysaccharides extract, neutral 1 part of notoginseng polysaccharide extract.
Any of the above-described scheme is preferably, in addition to pharmaceutic adjuvant.Pharmaceutic adjuvant includes sucrose, starch, maltodextrin, honeybee
Honey, benzic acid sodium, ethyl hydroxy benzoate, magnesium stearate, protein sugar etc..
Any of the above-described scheme is preferably, and its formulation is any one in granule, tablet, capsule or oral liquid.
The present invention also provides the preparation method of above-mentioned jujube complex polysaccharide composition, comprises the following steps：
(1) extraction of date polysaccharide；
(2) extraction of LBP-X；
(3) extraction of tremella polysaccharides；
(4) extraction of neutral notoginseng polysaccharide；
(5) said extracted thing, packing are mixed according to weight proportion.
Any of the above-described scheme is preferably, and the extraction specific method of date polysaccharide is in the step (1)：Jujube is crushed,
Many times of amount water immersions are added, multi-reflow extracts, discards filter residue merging filtrate, concentrate, add ethanol alcohol precipitation, pump supernatant and obtain
To precipitating and drying, dried powder is obtained.
Any of the above-described scheme is preferably, and the specific method of the alcohol precipitation is：The filtrate of separating and filtering, is concentrated into 1.06,
3 times of 95% ethanol is added to alcohol content 75%, the alcohol precipitation time is 24h.
Any of the above-described scheme is preferably, and the specific method that the multi-reflow is extracted is：The 8-10 times of water measured is added, just
Secondary refluxing extraction 5-8h, filters out solution, adds the 5-10 times of secondary water measured refluxing extraction 2-4h, filters out solution, add 4-6
Three water refluxing extraction 2-4h of amount, discard filter residue merging filtrate again.
Any of the above-described scheme is preferably, and the extraction specific method of LBP-X is in the step (2)：Matrimony vine adds many
Amount water immersion again, multi-reflow is extracted, merging filtrate, concentration, separating and filtering solution, and addition ethanol alcohol precipitation, is pumped after concentration
Clear liquid is precipitated and dried, and obtains dried powder.
Any of the above-described scheme is preferably, and the specific method that the multi-reflow is extracted is：Water is measured in first 9-11 times of addition
Immersion 12 hours, first refluxing extraction 5-8h filters out solution, adds the 4-10 times of water measured refluxing extraction 2-4h, secondary to filter out
Solution, adds three refluxing extraction 2-4h of the 3-5 times of water measured, discards filter residue merging filtrate afterwards.
Any of the above-described scheme is preferably, and the extraction specific method of tremella polysaccharides is in the step (3)：White fungus adds many
Amount water immersion again, multi-reflow is extracted, merging filtrate, concentration, and addition ethanol alcohol precipitation pumps supernatant and precipitated and dried,
Obtain dried powder.
Any of the above-described scheme is preferably, and the specific method that the multi-reflow is extracted is：Water is measured in first 48-52 times of addition
Immersion 12 hours, first refluxing extraction 5-8h filters out solution, adds the 30-40 times of water measured refluxing extraction 3-5h, secondary to filter out
Solution, merging filtrate.
Any of the above-described scheme is preferably, and neutral notoginseng polysaccharide is by extracting arasaponin in the step (4)
Waste residue, through water extract-alcohol precipitation, DEAE Sepharose Fast Flow anion-exchange chromatographies after purification gained.
Any of the above-described scheme is preferably, and also includes adding wheat into mixed extract before dispensing in the step (5)
Bud dextrin, after mixing, adds 95% appropriate amount of ethanol, crosses the granulation of 14 eye mesh screens, and drying is crossed 20 eye mesh screens and arranged, packing.Point
It can also can be dispensed again after tabletting with direct packaging during dress.
The present invention also provide above-mentioned jujube complex polysaccharide composition improve immunity, improve it is One's spirits are drooping, physically weak it is weak,
Application in appetite reduction, nausea and vomiting, loose stool diarrhea, irritated insomnia.
The present invention also provides above-mentioned jujube complex polysaccharide composition applied to health food.
The present invention also provides above-mentioned jujube complex polysaccharide composition applied to cosmetics.
The present invention also provides above-mentioned jujube complex polysaccharide composition applied to daily chemical product.Jujube in this formula is sandlwood
The ripening fruits of section's plant jujube.Chinese medicine theory thinks that jujube has the effect such as tonify deficiency benefit health, nourishing blood and tranquilization, strengthening the spleen and stomach,
It is the good health nutrient of the patient such as weakness of the spleen and the stomach, insufficiency of vital energy and blood, lassitude, insomnia and dreamful sleep.Date polysaccharide has a variety of
Pharmacological activity, date polysaccharide is the main active of jujube qi-supplementing, blood-engendering, and date polysaccharide is equal to the various active oxygens in human body
It is turned into antioxygen, repairs hepatic injury, antifatigue effect, immunocompetence, improvement enteron aisle, the suction for suppressing tumour cell and promotion calcium
Receive.
Matrimony vine, is the traditional rare traditional Chinese medicine of China, " red treasured " laudatory title is have, rich in plant polyose, protein, vitamin etc.
Nutritional ingredient.LBP-X is a kind of water-soluble polysaccharide obtained by extraction from matrimony vine.The clear and definite polysaccharide system proteoglycan, by
Arabinose, glucose, galactolipin, mannose, xylose, 6 kinds of monosaccharide components compositions of rhamnose.With promote T, B, CTL, NK and
The immunologic functions such as macrophage, promote the cell factors such as IL-2, IL-3 and TNF β to produce.Strengthen lotus knurl, chemotherapy and radiation injury
Immune function of mice and regulation neuro-endocrine-immunoregulatory adjust the effect of (NIM) network.
White fungus (Tremella fuciformisBerk), is commonly called as obtaining white fungus in tremella, fructification many
(Tremellam) be a kind of acid heteroglycan, its backbone structure be by the mannosan of α-(1 → 3) glycosidic bond connection, side chain by
Glucuronic acid and xylose composition.For Basidiomycetes polysaccharide para-immunity reinforcing agent, with improving body's immunity and lifting is white thin
The effect of born of the same parents.The phagocytic function of experimental animal reticuloendothelial cell is remarkably improved, has promotion nospecific immunity effect, improves
The level of immunoglobulin, total complement of serum.The marrow as caused by radiation with antineoplastic (such as CTX) can be prevented and treated to press down
System, can also promote the synthesis of liver internal protein.
Pseudo-ginseng waste residue of the present invention to extract notoginsenoside in producing, using water extraction and alcohol precipitation method, obtains neutrality as raw material
Pseudo-ginseng roughly polysaccharide, purifies pseudo-ginseng Thick many candies, in obtaining using DEAE Sepharose Fast Flow anion-exchange chromatographies
Property notoginseng polysaccharide PNPS I, study its influence to Periodontal ligament stem cell, it was demonstrated that neutral notoginseng polysaccharide PNPS I promote periodontal
The effect of film stem cell is more obvious, acts on and protruding in terms of body immunity is improved.
The present invention provides a kind of jujube complex polysaccharide composition and its preparation method and application, respectively with jujube, white fungus
Entity, the fruit of Chinese wolfberry, pseudo-ginseng, pseudo-ginseng are the waste residue for extracting arasaponin, extract date polysaccharide, tremella polysaccharides, LBP-X,
Neutral notoginseng polysaccharide, yield is respectively 6.5-6.9%, 12.0-21.0%, 2.8-4.4%, 0.32-0.42%, sulfuric acid-anthrone
It is respectively 48-58%, 37-41%, 28-34%, 80-94% that method, which determines polyoses content,.This formula contributes to immunocompromised person
And tumor patient strengthen immunity, improve One's spirits are drooping, physically weak weak, appetite reduction, nausea and vomiting, loose stool diarrhea, irritated mistake
The symptoms such as dormancy, effectively mitigate the harm of chemicotherapy and operation to tumour patient.
Brief description of the drawings
Fig. 1 is neutral notoginseng polysaccharide PNPSI High Performance Gel Permeation chromatogram.
Embodiment
In order to further appreciate that the technical characteristic of the present invention, the present invention is explained in detail with reference to specific embodiment
State.Embodiment only has exemplary effect to the present invention, without any restricted effect, those skilled in the art
The modification for any unsubstantiality made on the basis of the present invention, should all belong to protection scope of the present invention.
Embodiment 1
The present invention be made up of following raw materials, date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, in
Property notoginseng polysaccharide extract and pharmaceutically acceptable pharmaceutic adjuvant composition.Pharmaceutic adjuvant include sucrose, starch, maltodextrin,
Honey, benzic acid sodium, ethyl hydroxy benzoate, magnesium stearate, protein sugar etc..
The jujube complex polysaccharide composition of the present invention, including date polysaccharide extract 0.5-5kg, Lycium barbarum polysaccharide extract
0.5-5kg and tremella polysaccharides extract 0.5-5kg, neutral notoginseng polysaccharide extract 0-5kg, add suitable pharmaceutic adjuvant, mix,
The appropriate amount of ethanol for plus 95%, crosses the granulation of 14 eye mesh screens, and drying is crossed 20 eye mesh screens and arranged, is distributed into 1000 bags.Packing is prepared into
The peroral dosage forms such as granula, tablet, capsule, oral liquid.
In 1 bag of jujube complex polysaccharide composition of the invention, adult's recommendation consumption is：One day 2-3 times, one time 1-2 bags.
The preparation method of jujube complex polysaccharide composition of the present invention, including the steps：
(1) extraction of date polysaccharide extract and assay
400 kilograms of jujube is weighed, is crushed, 8 times of amount water is added and soaks 12 hours, refluxing extraction 8h filters out solution, medicinal material is again
The water refluxing extraction 4h of 5 times of amounts is added, solution is filtered out, medicinal material adds the water refluxing extraction 4h of 4 times of amounts, filter residue is discarded and merges filter
Liquid, is concentrated into 1.06, adds 3 times of 95% ethanol to alcohol content 75%, the alcohol precipitation time is 24h, and pumping supernatant must precipitate and do
It is dry, 27.60 kilograms of dried powder is obtained, yield is 6.90%.Precision weighs powder in right amount, and H2SO4-anthrone method determines date polysaccharide
Content is 57.17%.
(2) extraction of Lycium barbarum polysaccharide extract and assay
400 kilograms of matrimony vine is weighed, 10 times of amount water is added and soaks 12 hours, refluxing extraction 8h filters out solution, and medicinal material is added
The water refluxing extraction 4h of 5 times of amounts, filters out solution, and medicinal material adds the water refluxing extraction 4h of 4 times of amounts, discards filter residue merging filtrate,
Density is concentrated into 1.06, it is 75% to add 3 times of 95% ethanol to amount of alcohol, and the alcohol precipitation time is 24h, and pumping supernatant must precipitate
And dry, 11.20 kilograms of dried powder is obtained, yield is 2.80%.Precision weighs powder in right amount, and H2SO4-anthrone method determines matrimony vine
Polyoses content is 33.50%.
(3) extraction of tremella polysaccharides extract and assay
400 kilograms of white fungus is weighed, 50 times of amount water is added and soaks 12 hours, refluxing extraction 8h filters out solution, and medicinal material is added
The water refluxing extraction 4h of 30 times of amounts, filters out solution, and merging filtrate is concentrated into density to 1.06, adds 3 times of 95% ethanol to ethanol
Measure as 75%, the alcohol precipitation time is 24h, pumping supernatant must precipitate and dry, and obtain 47.84 kilograms of dried powder, yield is
11.96%.Precision weighs powder in right amount, and it is 37.00% that H2SO4-anthrone method, which determines tremella polysaccharides content,.
(4) extraction of neutral notoginseng polysaccharide and assay
(4.1) extraction of pseudo-ginseng Thick many candies：The waste residue 1kg for extracting arasaponin is weighed, 10 times of amounts are added for the first time
Water, boiling water bath boils 8h, collects filtrate, second of addition, 5 times of amount water, boiling water bath 8h.Merge filtrate twice, 4500rpm centrifugations
5min, takes supernatant.80 DEG C of spin concentrations stand 24h to the 1/8 of original volume, and centrifugation abandons precipitation, is slowly added to the anhydrous second of three times
Alcohol, stirring while adding, 4 DEG C of placement 12h, suction filtration must be precipitated.75% ethanol washing precipitation for several times, ethanol is volatilized after doing with appropriate
Water is dissolved, centrifugation, collects supernatant, adds three times absolute ethyl alcohol, and 4 DEG C of placement 12h, suction filtration must be precipitated, 75% ethanol washing precipitation,
50 DEG C of oven for drying, produce pseudo-ginseng Thick many candies.
(4.2) DEAE Sepharose Fast Flow anion-exchange chromatographies purifying Thick many candies
(4.2.1) fills post：Wet method dress post, pillar fills in cotton, and post is interior to be added distilled water and keep a bit of liquid level, glass
Rod pressing cotton dispels bubble.It is poured slowly into glass bar guiding homogenate along column wall in post, it is impossible to produce bubble.Open pillar
Liquid outlet, makes gel free settling in post, chromatographic column edge is cleaned with water.There can not be tomography during dress post, then use distilled water
Balance, post specification is 2.4 × 40cm.
(4.2.2) loading：Pseudo-ginseng Thick many candies are dissolved in a small amount of distilled water, are configured to 30mg/mL, 4500rpm centrifugations
10min, 0.45 μm of filter filtering of supernatant, loading.During loading, chromatographic column liquid outlet is opened, it is to be distilled to move to post bed under water
During surface, liquid outlet is closed, notoginseng polysaccharide solution is added along column wall with dropper, opens liquid outlet, allow sample liquid all to flow into
Column interior, and with a small amount of distilled water flushing column wall, then go and elute.
(4.2.3) is eluted：It is eluted with water, elutes about 5 times of column volumes, flow velocity is 0.8mL/min, often pipe meets 2mL, depressurizes dense
It is reduced to 1/10 volume.
(4.2.4) dialyses：Bag filter is cut into every section of about 10cm, is put in distilled water and boils 30min, boiled again after washing three times
Boil 10min, distilled water wash clean.Bag filter can be used three times, and 2%NaHCO is used for the second time3After being boiled with 1mmol/L EDTA
Cleaning.Respectively by bag filter of the eluent after concentration loaded on molecular weight 14000, about 1/2 volume is clamped with dialysis clamp and dialysed
Bag two ends, are put in distilled water the 36h that dialyses, and a water is changed per 4h.
(4.2.5) is freeze-dried：Eluent is collected in 50mL centrifuge tubes, about 16mL, -40 DEG C of pre-freeze 12h is filled, is put in cold
The dissolving of about 1mL distilled water is added after lyophilizer 36h, taking-up, is shaken up.- 40 DEG C of pre-freeze 12h, are put in freeze drier 24h.Take
Seal and preserved in drier after going out.Anthrone-sulfuricacid method determines neutrality notoginseng polysaccharide PNPS I, PNPS I (neutral notoginseng polysaccharide)
Content 93.6%, yield 28.9%, number-average molecular weight is 11170, and weight average molecular weight is 31590, polydispersity coefficient D (Mw/
Mn it is) 2.828, neutral notoginseng polysaccharide PNPS I High Performance Gel Permeation chromatogram is as shown in Figure 1.
(4.3) mtt assay determines influence of the neutral notoginseng polysaccharide to Periodontal ligament stem cell in-vitro multiplication
Using regular growth cultivation culture cell.The Periodontal ligament stem cell of 7 generation exponential phases is taken, adjusts thin after counting
Born of the same parents' concentration, is inoculated in 96 orifice plates, 100/hole, every hole 90 μ l, CO2Incubator culture adds neutral notoginseng polysaccharide respectively after 12 hours
(PNPS I) and each 10 μ l of pseudo-ginseng Thick many candies solution, make to act on the final concentration of 6.72mg/ml of cell, 4.48mg/ml,
2.24mg/ml, 1.12mg/ml, 560ug/ml, 280ug/ml, 140ug/ml, 70ug/ml, each concentration set 6 parallel holes, cloudy
Property control be isometric MEM-ALPHA nutrient solutions, plus μ l of physiological saline 10.After 48 hours, plus the μ l of MTT solution (5mg/ml) 20 every
Hole, continues to cultivate 4 hours, and 150 μ lDMSO are added per hole and are fully dissolved, the A570 values in each hole are determined with ELIASA.Calculate different
The A570 of concentration OD values, experimental result is shown in Table 1：
Influence experimental result (n=6) of the notoginseng polysaccharide of table 1 to Periodontal ligament stem cell in-vitro multiplication
Note：*P<0.05；**P<0.01
The data in table 1, neutral notoginseng polysaccharide PNPS I is in 35~1120ug/ml of concentration, to Periodontal ligament stem cell
With obvious Effect of promoting growth；Relative to pseudo-ginseng Thick many candies, increasings of the neutral notoginseng polysaccharide PNPS I to Periodontal ligament stem cell
Grow facilitation more notable.
The jujube complex polysaccharide granule of embodiment 2
Plus appropriate maltodextrin, mix, the appropriate amount of ethanol for plus 95%, cross the granulation of 14 eye mesh screens, drying crosses 20 eye mesh screens whole
Reason, is distributed into 1000 bags.
Date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, neutral notoginseng polysaccharide in the present embodiment
The preparation method of extract is and embodiment 1 is identical.
The jujube complex polysaccharide tablet of embodiment 3
Plus appropriate maltodextrin, mix, the appropriate amount of ethanol for plus 95%, cross the granulation of 14 eye mesh screens, drying crosses 20 eye mesh screens whole
Reason, tabletting, film coating, packing.
Date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, neutral notoginseng polysaccharide in the present embodiment
The preparation method of extract is and embodiment 1 is identical.
The jujube complex polysaccharide tablet of embodiment 4
Plus appropriate maltodextrin, mix, the appropriate amount of ethanol for plus 95%, cross the granulation of 14 eye mesh screens, drying crosses 20 eye mesh screens whole
Reason, tabletting, film coating, packing.
Date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, neutral notoginseng polysaccharide in the present embodiment
The preparation method of extract is and embodiment 1 is identical.
The jujube complex polysaccharide granule of embodiment 5
Plus appropriate maltodextrin, mix, the appropriate amount of ethanol for plus 95%, cross the granulation of 14 eye mesh screens, drying crosses 20 eye mesh screens whole
Reason, is distributed into 1000 bags.
Date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, neutral notoginseng polysaccharide in the present embodiment
The preparation method of extract is and embodiment 1 is identical.
The jujube complex polysaccharide granule of embodiment 6
Plus appropriate maltodextrin, mix, the appropriate amount of ethanol for plus 95%, cross the granulation of 14 eye mesh screens, drying crosses 20 eye mesh screens whole
Reason, is distributed into 1000 bags.
Date polysaccharide extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract, neutral notoginseng polysaccharide in the present embodiment
The preparation method of extract is and embodiment 1 is identical.
Embodiment 7
Leukopenic observation of curative effect after jujube complex polysaccharide composition treatment malignant tumor chemotherapy
7.1 data and method
7.1.1 data
Neuroleptic Leukocytopenia patient caused by after in June, 2015~2016 year malignant tumor chemotherapy in June is chosen (to demonstrate,prove by pathology
It is real), exclude and use other shengbai drugs person, KPS scorings >=60 points, include this research for 50 altogether.It is randomly divided into observation
With control group each 10, man 4 in observation group, female 6, average age (54.2 ± 7.3) year, breast cancer 4, cervical cancer 2 example,
Colorectal cancer 2, lung cancer 2.
In control group A man 5, female 5, average age be (53.9 ± 10.6) year, breast cancer 2, liver cancer 3, large intestine
Cancer 1, lung cancer 3, stomach cancer 1.In control group B man 6, female 4, average age be (54.1 ± 9.3) year, breast cancer 2,
Liver cancer 3, colorectal cancer 1, lung cancer 2, stomach cancer 2.Man 5 in control group C, female 5, average age is (53.6 ± 10.9)
Year, mammary cancer 1 example, liver cancer 3, colorectal cancer 2, lung cancer 4.In control group D man 6, female 4, average age for (53.7 ±
10.8) year, breast cancer 3, liver cancer 4, stomach cancer 3.
Four groups in sex composition, average age, KPS scorings, tumour classification there are no significant difference (P>0.05), with can
Compare property.
7.1.2 treatment method
Observation group give prepared in embodiment 2 jujube complex polysaccharide composition (date polysaccharide 4.5g, LBP-X 1.0g,
Tremella polysaccharides 0.5g, neutrality notoginseng polysaccharide 0.5g) each 1 time sooner or later, once two bags, it even served 3 weeks.
Control group A gives batyl alcohol 100mg, leucogen 20mg, 3 times/d, even served 3 weeks.Close observation is various simultaneously during treatment
Send out the generation of disease.
Control group B takes product prepared by the patent of invention embodiment 1 that number of patent application is 201210532229.0, daily
Twice, three weeks be even served.
Control group C takes the jujube complex polysaccharide granule of the preparation of embodiment 5, twice daily, even served three weeks.
Control group D takes the jujube complex polysaccharide granule of the preparation of embodiment 6, twice daily, even served three weeks.
7.1.3 observation index and the standard of curative effect evaluation
Periphery blood routine is checked during treatment 2 times a week.According to the Ministry of Public Health《Clinical drug studies guideline》Middle formulation
Increasing leukocyte criterion of therapeutical effect, it is effective：WBC sums>4.0 × 109/L, can maintain curative effect to being discontinued 1 week, clinical symptoms significantly subtract
Light or disappearance；Effectively：WBC sums<4.0 × 109/L, than rising (0.5-1.0) × 109/L before treatment, can maintain curative effect to stopping
Medicine 1 week, clinical symptoms take a turn for the better；It is invalid：WBC sums increase<0.5 × 109/L, clinical symptoms are without improvement.
7.2 treatment results
After treatment data result is shown in Table 2, and observation group relative comparison group A, control group B, control group C, control group D control curative effect
Fruit is more notable.Observation group has no adverse reaction.
Effect data after table 2 is treated
Clinical rush leucocyte medicine conventional at present, such as leucogen, batyl alcohol, effect is slow, and effect is not notable.And inject
Though the leukogenic effects such as class medicine G-CSF significantly, have rebound phenomenon, occur that ostalgia, heating etc. are secondary anti-during heavy dose application
Should, and price is relatively expensive.Therefore eager demand determined curative effect, super quality and competitive price, the medicine of Small side effects.
Occurs the patient of leucocyte reduction after data in table 2, chemotherapy, jujube prepared by Application Example 2 is answered
Close after polysaccharide composition, soreness and weakness of waist and knees, dizzy, spiritlessness and weakness, deficiency of food are indigestion and loss of appetite etc., and deficiency of spleen and stomach symptom has clear improvement,
KPS scorings before medication compared with being significantly improved.DeGrain after control group A, control group B and control group C, control group D treatments.
The above results show that jujube complex polysaccharide composition can treat leucocyte caused by chemotherapy of tumors to a certain extent
Reduce, so as to ensure being normally carried out for chemotherapy, extend patient survival.
Claims (10)
1. a kind of jujube complex polysaccharide composition, is made by mixing using plurality of raw materials extract and formed, it is characterised in that：Including big
Jujube polyoses extract, Lycium barbarum polysaccharide extract, tremella polysaccharides extract and neutral notoginseng polysaccharide extract.
2. jujube complex polysaccharide composition according to claim 1, it is characterised in that：Include the extraction of following parts by weight
Thing:0.5-5 parts of date polysaccharide extract, 0.5-5 parts of Lycium barbarum polysaccharide extract, 0.5-5 parts of tremella polysaccharides extract, neutral pseudo-ginseng
0-5 parts of polyoses extract.
3. jujube complex polysaccharide composition according to claim 1, it is characterised in that：Include the extraction of following parts by weight
Thing:4.5 parts of date polysaccharide extract, 1 part of Lycium barbarum polysaccharide extract, 4.5 parts of tremella polysaccharides extract, neutral notoginseng polysaccharide are extracted
1 part of thing.
4. jujube complex polysaccharide composition according to claim 1, it is characterised in that：Include the extraction of following parts by weight
Thing:2 parts of date polysaccharide extract, 1 part of Lycium barbarum polysaccharide extract, 2 parts of tremella polysaccharides extract, neutral notoginseng polysaccharide extract 2
Part.
5. jujube complex polysaccharide composition according to claim 1, it is characterised in that：Also include pharmaceutic adjuvant.
6. jujube complex polysaccharide composition according to claim 1, it is characterised in that：Its formulation is granule, tablet, glue
Any one in wafer or oral liquid.
7. the preparation method of the jujube complex polysaccharide composition according to any one claim in claim 1-5, its
It is characterised by：Comprise the following steps：
（1）The extraction of date polysaccharide；
（2）The extraction of LBP-X；
（3）The extraction of tremella polysaccharides；
（4）The extraction of neutral notoginseng polysaccharide；
（5）Said extracted thing, packing are mixed according to weight proportion.
8. the preparation method of jujube complex polysaccharide composition according to claim 7, it is characterised in that：The step（1）
The extraction specific method of middle date polysaccharide is：Jujube is crushed, and adds many times of amount water immersions, and multi-reflow is extracted, and discards filter residue conjunction
And filtrate, concentration, ethanol alcohol precipitation is added, supernatant is pumped and is precipitated and dried, obtain dried powder.
9. jujube complex polysaccharide composition according to any one of claim 1 to 6 is applied to health food.
10. jujube complex polysaccharide composition according to any one of claim 1 to 6 is applied to cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710465590.9A CN107281212B (en) | 2017-06-19 | 2017-06-19 | A kind of jujube complex polysaccharide composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710465590.9A CN107281212B (en) | 2017-06-19 | 2017-06-19 | A kind of jujube complex polysaccharide composition and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107281212A true CN107281212A (en) | 2017-10-24 |
| CN107281212B CN107281212B (en) | 2018-10-23 |
Family
ID=60097265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710465590.9A Active CN107281212B (en) | 2017-06-19 | 2017-06-19 | A kind of jujube complex polysaccharide composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281212B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600494A (en) * | 2012-03-30 | 2012-07-25 | 武汉华纳联合药业有限公司 | Polysaccharide combination and preparation method and application thereof |
| CN102949407A (en) * | 2011-08-19 | 2013-03-06 | 上海辰川生物技术发展有限公司 | Application of Achyranthes bidentata polysaccharides |
| CN104509765A (en) * | 2014-12-04 | 2015-04-15 | 黄亚辉 | Immunity improving drug and preparation process thereof |
-
2017
- 2017-06-19 CN CN201710465590.9A patent/CN107281212B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949407A (en) * | 2011-08-19 | 2013-03-06 | 上海辰川生物技术发展有限公司 | Application of Achyranthes bidentata polysaccharides |
| CN102600494A (en) * | 2012-03-30 | 2012-07-25 | 武汉华纳联合药业有限公司 | Polysaccharide combination and preparation method and application thereof |
| CN104509765A (en) * | 2014-12-04 | 2015-04-15 | 黄亚辉 | Immunity improving drug and preparation process thereof |
Non-Patent Citations (2)
| Title |
|---|
| 盛卸晃等: "三七多糖的分离纯化及理化性质研究", 《中草药》 * |
| 马兴铭等: "中药多糖对小鼠巨噬细胞功能影响的比较", 《甘肃中医学院学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107281212B (en) | 2018-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN1706473A (en) | Anticancer taxad Chinese medicine prepn | |
| CN105148258A (en) | Composition and application thereof, and preparation containing composition | |
| CN101067006A (en) | Low molecular Brazil mushroom polysaccharide and its prepn process and application in antagonizing tumor metastasis | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN108713746A (en) | A kind of integration of drinking and medicinal herbs composition and its preparation method and application | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN108567820A (en) | A kind of Chinese medicine composition and preparation method thereof for oncotherapy | |
| CN110343185A (en) | A kind of wine RHIZOMA POLYGONATI PREPARATA polysaccharide and its purposes in terms of spleen deficiency Immunity regulation | |
| CN102641331A (en) | Auxiliary anti-tumor medicament, traditional Chinese medicine mixture and preparation method thereof | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN104857436B (en) | Traditional Chinese medicine compound composition with resisting liver cancer activity and its preparation method and application | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN107281212B (en) | A kind of jujube complex polysaccharide composition and its preparation method and application | |
| CN109528807A (en) | A kind of Chinese medicine composition and its preparation method and application enhanced human immunity | |
| CN107890542A (en) | Treat the Chinese medicine composition and its preparation method of diarrhoea | |
| CN114848786A (en) | Compound Sanshen decoction for resisting cancer and increasing immunity | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN107174592B (en) | A kind of Hericium erinaceus complex polysaccharide composition and its preparation method and application | |
| CN102805799A (en) | Traditional Chinese medicine composition with antitumous effect | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN103169844B (en) | Traditional Chinese medicine composition having anti-lung cancer and anti-liver cancer effects | |
| CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
| CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN101011543B (en) | Antineoplastic medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |